LINE250117P130000
- 0.00
- 0.000.00%
Lineage Newsroom
Maxim Group Maintains Buy on Lineage Cell Therapeutics, Lowers Price Target to $3
Lineage Is Maintained at Neutral by Mizuho
Mizuho Securities Maintains Lineage(LINE.US) With Hold Rating, Cuts Target Price to $67
Express News | Lineage Inc : UBS Cuts Target Price to $64 From $75
Lineage Cell Price Target Lowered to $2 From $3 at D. Boral Capital
D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target
Lineage Cell Therapeutics Analyst Ratings
Daily short sale tracking: Intel's short volume increased by 4 million, with a short sale ratio of 18%
Intel(INTC.US) ranked top of the list had the largest change in short volume (4.38 million shares), and the short volume ratio of Lineage(LINE.US) reached 52.14%. See more about the top 10 list of short selling volume changes in the latest trading day of the US stock market.
Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $95
Is Lineage, Inc. (LINE) the Best New Stock to Buy According to Hedge Funds?
Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $95
Positive Outlook and Strategic Positioning Drive Buy Rating for Lineage, Inc.
Wall Street's IPO Engine Picked Up in 2024 -- Barrons.com
Real Estate Stocks End in Red With the Pace of Rate Cuts Expected to Slow in 2025
J.P. Morgan Downgrades Lineage(LINE.US) to Hold Rating, Cuts Target Price to $75
J.P. Morgan Downgrades Lineage, Inc. (LINE) to a Hold
J.P. Morgan Revises Ratings on Five REITs Ahead of 2025
Lineage Cut to Neutral From Overweight by JP Morgan
JP Morgan Downgrades Lineage to Neutral, Lowers Price Target to $75
InterVision Wins First-Ever AWS GenAI Builder Bonanza Contest, Demonstrating Excellence in AI Sovereignty and Data Lineage